###### 

Resource table.

  -------------------------------------- -----------------------------------------------------------------------------------------------------------------
  Unique stem cell lines identifier      NIHTVBi001-A\
                                         NIHTVBi002-A\
                                         NIHTVBi003-A

  Alternative names of stem cell lines   iPSCp117\
                                         iPSCp118\
                                         iPSCp120

  Institution                            National Heart, Lung, and Blood Institute (NHLBI), National Institutes of Health (NIH), Bethesda, Maryland, USA

  Contact information of distributor     Manfred Boehm; <boehmm@nhlbi.nih.gov>

  Type of cell lines                     iPSC

  Origin                                 Human

  Cell Source                            Dermal fibroblasts

  Clonality                              Clonal cell lines

  Method of reprogramming                Lentiviral vectors

  Multiline rationale                    Lines derived from the three individuals

  Gene modification                      None

  Type of modification                   N/A

  Associated disease                     None

  Gene/locus                             CCR5, 3p21.31

  Method of modification                 N/A

  Name of transgene or resistance        N/A

  Inducible/constitutive system          N/A

  Date archived/stock date               December 2013

  Cell line repository/bank              N/A

  Ethical approval                       National Institutes of Health Ethics Committee (Approval Number: 10-H-0126)
  -------------------------------------- -----------------------------------------------------------------------------------------------------------------

Resource utility {#S1}
================

Human induced pluripotent stem cells (hiPSCs) containing CCR5Δ32 provide an important model to better understand the mechanisms regulating the functions of CCR5 in immune cells and HIV pathophysiology. Meanwhile, these iPSCs could offer a novel strategy for developing stem cell therapy to treat individuals with HIV/AIDS.

Resource details {#S2}
================

CCR5 is a receptor for β-chemokines, including macrophage inflammation proteins 1α and 1β and RANTES. The expression and regulation of CCR5 in human immune cells are implicated not only in inflammatory diseases but are also involved in viral infections such as HIV ([@R5]; [@R1]). This observation makes CCR5 an attractive target for developing treatment for individuals with HIV/AIDS. Several research groups have attempted to disrupt the *CCR5* gene in CD34^+^ hematopoietic stem/progenitor cells, CD4^+^ T cells, and hiPSCs by using gene editing. However, the effects of integration mutagenesis could potentially cause other complications, such as safety issues relating to long-term treatment ([@R3]). The naturally occurring CCR5Δ32 variant is barely rare; it has been observed in less than 1% of most European-derived populations and is less common in other racial groups. Other than HIV-resistance, there are no known clinical effects of the homozygous CCR5Δ32 genotype ([@R4]).

We identified three individuals homozygous for the CCR5Δ32 variant by exome sequencing and enrolled them into one of our NHLBI clinical protocols (10-H-0126) for further investigations. Information regarding clinical onset were obtained using the standard clinical interview ([Table 1](#T1){ref-type="table"}). Skin punch biopsy samples from these three individuals were collected at the NIH Clinical Center. Using a Cre/loxP excisable lentiviral vector delivery system expressing four transcription factors (*OCT4, SOX2, KLF4*, and *C-MYC*), we successfully generated hiPSC lines from skin fibroblasts derived from three individuals with the naturally occurring homozygous CCR5Δ32 mutation (hiPSC-CCR5Δ32) and from healthy volunteers (hiPSC-Con) who did not have that variant. The reprogramming efficiency of these skin fibroblasts was the same for both groups (Data not shown). The hiPSC-CCR5Δ32 lines maintained typical morphologies and expressed the typical pluripotency markers OCT4, NANOG, TRA-1-60, SSEA4, and SOX2, as shown by immunocytochemistry ([Fig. 1A](#F1){ref-type="fig"}) and/or real-time (RT)-qPCR ([Fig. 1C](#F1){ref-type="fig"}). Genotyping of the generated hiPSC-CCR5Δ32 lines showed a 32-bp deletion in *CCR5* in all clones that were the same as their parental fibroblasts ([Fig. 1B](#F1){ref-type="fig"}). All three cell lines demonstrated chromosomal stability and a normal karyotype with G-banding ([Fig. 1D](#F1){ref-type="fig"}).

To test the differentiation potential of the cell lines, we performed a monolayer differentiation assay to drive the cells toward the three germ layers *in vitro.* We determined the marker gene expression for the mesoderm (*RUNX1*), endoderm (*AFP*), and ectoderm (*WES*) with RT-qPCR, which showed comparable expression levels between the hiPSC-CCR5Δ32 and hiPSC-Con line ([Fig. 1C](#F1){ref-type="fig"}). Short tandem repeat (STR) profiles indicated that all hiPSC-CCR5Δ32 lines matched with their parental fibroblasts completely in 15 amplified STR loci (see [Supplementary File 1](#SD1){ref-type="supplementary-material"}). All cultures were routinely tested for *Mycoplasma* contamination and were found to be *Mycoplasma* free as shown in [Supplementary File 2](#SD2){ref-type="supplementary-material"}. Notably, CCR5 was not expressed in iPSCs. hiPSC-CCR5Δ32 lines exhibited a similar pluripotent potential for self-renew and proliferation as hiPSC-Con line, suggesting that CCR5 is dispensable for reprogramming of fibroblasts and maintenance of stemness.

To the best of our knowledge, this is the first published study in which hiPSC lines were generated from individuals with the naturally occurring a homozygous CCR5Δ32 mutation ([Table 2](#T2){ref-type="table"}).

Materials and methods {#S3}
=====================

Subjects and study approval {#S4}
---------------------------

iPSCs were generated from fibroblasts derived from skin punch biopsy samples obtained from three individuals with the homozygous CCR5Δ32 variant and healthy volunteers. This study was approved by the NHLBI's institutional review board, and samples were collected after obtaining informed written consents.

Derivation of fibroblasts {#S5}
-------------------------

Fibroblasts derived from individuals with the homozygous CCR5Δ32 variant and healthy volunteers were collected from explants of 4-mm skin punch biopsy specimens and grown in Dulbecco's modified Eagle's medium (DMEM) containing 10% fetal calf serum and 1% penicillin-streptomycin, as previously described ([@R2]). After 1--2 weeks, fibroblast outgrowths from the explants were passaged.

Generation and culture of human iPSCs from fibroblasts {#S6}
------------------------------------------------------

Fibroblasts from individuals with the homozygous CCR5Δ32 variant were reprogrammed to generate iPSC lines by transduction with the Human STEMCCA Cre-Excisable Constitutive Polycistronic (OKSM) Lentivirus Reprogramming Kit (Millipore). iPSC colonies were collected at 21 days post-transduction, and expanded in a typical hESC/iPSC culture condition ([@R2]).

Immunofluorescent staining {#S7}
--------------------------

iPSCs were fixed with 4% paraformaldehyde and stained following the previous protocol ([@R2]). In brief, cells were incubated with primary antibodies against NANOG, OCT4, SSEA4, or TRA-1-60 ([Table 3](#T3){ref-type="table"}) at 4 °C overnight. Following washing with PBS, they were incubated with appropriate fluorophore-tagged secondary antibodies at room temperature for 1 h. After washing with PBS, nuclei were stained with DAPI. Images were captured using a fluorescence microscope (Zeiss).

Monolayer differentiation assay {#S8}
-------------------------------

To assess iPSCs' ability to differentiate *in vitro*, cell cultures were dissociated into small clumps with 0.5 μM EDTA and cultured on Matrigel Precoated Plates (Corning) with differentiation medium consisting of 90% KnockOut DMEM, 10% FBS, 2mM [l]{.smallcaps}-glutamine, 0.1 mM non-essential amino acids, and 0.1 mM 2-mercaptoethanol (Invitrogen). After seven days, cells were harvested for further analysis.

Gene expression analysis {#S9}
------------------------

The total RNA was isolated by using RNeasy Mini Kits (Qiagen). Endogenous mRNA expression levels of *NANOG, SOX2, AFP, NES*, and *RUNX1* were determined in iPSCs and in differentiating cells at day 7. For this, RT-qPCR was performed by using SYBR Green Premix on a Real-Time PCR Detection System (Bio-Rad). Assays were run in triplicate and the results were normalized to 18S ribosomal RNA expression. Primers used for RT-qPCR are shown in [Table 3](#T3){ref-type="table"}.

Karyotyping assay {#S10}
-----------------

The karyotype of the iPSCs was evaluated by the WiCell Research Institute using G-banding metaphase karyotype analysis.

DNA sequencing and STR {#S11}
----------------------

Genomic DNA was extracted by using DNeasy Blood & Tissue Kit (Qiagen). To amplify the corresponding deletion position in *CCR5*, PCR was performed with specific primers ([Table 3](#T3){ref-type="table"}). Following purification, the PCR products were sent to Eurofins Scientific for sequencing.

STR analysis was performed by WiCell Research Institute, which generated a STR profile *via* the Promega Powerplex® 16 System to verify STR polymorphisms for 15 loci plus amelogenin in genomic DNA extracted from iPSCs and their parental fibroblasts.

Mycoplasma detection {#S12}
--------------------

To validate the cultures of derived iPSCs were *Mycoplasma* free, media were collected after culturing for 48 h and analyzed by using the MycoAlert™ Mycoplasma Detection Kit (Lonza).

Supplementary Material {#SM1}
======================

This work was supported by the Intramural Research Program of the National Human Genome Research Institute, National Institutes of Health.

Appendix A. Supplementary data

Supplementary data to this article can be found online at <https://doi.org/10.1016/j.scr.2019.101481>.

![Characterization of human iPSC lines derived from three individuals homozygous for the CCR5Δ32 variant. (A) iPSCs were cultured to passage 15 on a feeder-coated plate. Phase contrast images of iPSC lines derived from three individuals homozygous for the CCR5 32-bp deletion (hiPSC-CCR5Δ32; lines p117, p118 and p120) (column 1). Expression of pluripotent markers (NANOG, OCT4, SSEA4, and TRA-1-60 was analyzed by immunofluorescence; DAPI staining of cell nuclei in blue (columns 2-5) (all scale bars: 100 μm). (B) PCR and DNA sequencing identified the 32-bp deletion in CCR5 in parental fibroblasts (top row) the iPSC lines (bottom row) from the three individuals (blue arrows), but not in those from a healthy volunteer (control). (C) Expression of pluripotent state genes (NANOG and SOX2) was confirmed in all hiPSC-CCR5Δ32 lines as assessed by RT-qPCR. All three hiPSC-CCR5Δ32 lines were able to differentiate into three germ layers using monolayer differentiation in vitro, as shown by gene expression of AFP, NESTIN and RUNX1. Data are represented as means ± SEM relative to mRNA levels. (D) All three hiPSC-CCR5Δ32 lines had a normal karyotype by G-band analysis.](nihms-1533534-f0001){#F1}

###### 

Summary of three individuals with a homozygous CCR5Δ32 variant.

  iPSC line names   Abbreviation in figures   Gender   Age (years)   Ethnicity           Genotype of locus   Disease
  ----------------- ------------------------- -------- ------------- ------------------- ------------------- ---------
  NIHTVBi001-A      p117                      F        60            European-American   *CCR5*, 3p21.31     None
  NIHTVBi00-2A      p118                      M        56            European-American   *CCR5*, 3p21.31     None
  NIHTVBi003-A      p120                      M        69            European-American   *CCR5*, 3p21.31     None

###### 

Characterization and validation.

  Classification                        Test                                                 Result                                                                                                                     Data
  ------------------------------------- ---------------------------------------------------- -------------------------------------------------------------------------------------------------------------------------- --------------------------------
  Morphology                            Phase-contrast microscope                            Normal                                                                                                                     [Fig. 1A](#F1){ref-type="fig"}
  Phenotype                             Qualitative analysis (immunofluorescence staining)   Expression of pluripotency markers: OCT4, NANOG, SSEA4 and TRA-1-60                                                        [Fig. 1A](#F1){ref-type="fig"}
                                        Quantitative analysis (RT-qPCR)                      Expression of pluripotency markers: *SOX2* and *NANOG*                                                                     [Fig. 1C](#F1){ref-type="fig"}
  Genotype                              Karyotype (G-banding) and resolution                 46,XX or 46,XY; resolution 450--500 bands                                                                                  [Fig. 1D](#F1){ref-type="fig"}
  Identity                              Microsatellite PCR OR STR analysis                   Not performed                                                                                                              N/A
                                                                                             15 sites tested, 100% match                                                                                                Supplementary file
  Mutation analysis (IF APPLICABLE)     DNA sequencing                                       Homozygous, *CCR5* 32-bp deletion                                                                                          [Fig. 1B](#F1){ref-type="fig"}
  Southern blot OR WGS                  Not performed                                        N/A                                                                                                                        
  Microbiology and virology             *Mycoplasma* testing by luminescence                 Negative                                                                                                                   Available from authors
  Differentiation potential             Monolayer differentiation assay                      Differentiating cells are expression of *RUNX1, AFP*, and *NES*; iPSCs were able to differentiate into three germ layers   [Fig. 1C](#F1){ref-type="fig"}
  Donor screening (OPTIONAL)            HIV1 + HIV2, hepatitis B virus, hepatitis C virus    Not performed                                                                                                              N/A
  Genotype additional info (OPTIONAL)   Blood group genotyping                               Not performed                                                                                                              N/A
  HLA tissue typing                     Not performed                                        N/A                                                                                                                        

###### 

Reagents.

  Antibodies used for immunoeytoehemistry                                                                                      
  ----------------------------------------- ------------------------------------ ------- --------------------------- --------- -------------
  Primary antibodies                        Rabbit anti-OCT4                     1:100   Cell Signaling Technology   2750      AB_823583
                                            Mouse anti-NANOG                     1:100   Cell Signaling Technology   4893      AB_10548762
                                            Mouse anti-SSEA4                     1:100   MilliporeSigma              MAB4304   AB_177629
                                            Mouse anti-TRA-1-60                  1:150   MilliporeSigma              MAB4360   AB_2119183
  Secondary antibodies                      Alexa Fluor 594 Donkey anti-rabbit   1:300   Life Technologies           A21207    AB_141637
                                            Alexa Fluor 594 Donkey anti-mouse    1:300   Life Technologies           A21203    AB_141633
                                            Alexa Fluor 488 Donkey anti-mouse    1:300   Life Technologies           A21202    AB_141607
                                            Alexa Fluor 555 Goat anti-mouse      1:300   Life Technologies           A21426    AB_2535847
